MX2018002906A - Metodos de tratamiento de trastornos del desarrollo con pipradrol. - Google Patents

Metodos de tratamiento de trastornos del desarrollo con pipradrol.

Info

Publication number
MX2018002906A
MX2018002906A MX2018002906A MX2018002906A MX2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A MX 2018002906 A MX2018002906 A MX 2018002906A
Authority
MX
Mexico
Prior art keywords
methods
pipradrol
developmental disorders
treating developmental
syndrome
Prior art date
Application number
MX2018002906A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2018002906A publication Critical patent/MX2018002906A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para tratar trastornos del desarrollo administrando una composición farmacéutica de pipradrol o una sal farmacéuticamente aceptable del mismo. Los métodos se pueden usar para tratar condiciones como epilepsia, síndrome de Landau-Kleffner, síndrome de Lennox-Gastaut (LGS) y el síndrome de Dravet.
MX2018002906A 2015-09-09 2016-09-08 Metodos de tratamiento de trastornos del desarrollo con pipradrol. MX2018002906A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562215831P 2015-09-09 2015-09-09
US14/876,110 US9351968B1 (en) 2015-09-09 2015-10-06 Methods of treating developmental disorders using pipradrol
US15/147,429 US20170065572A1 (en) 2015-09-09 2016-05-05 Methods of treating developmental disorders using pipradrol
PCT/US2016/050702 WO2017044578A1 (en) 2015-09-09 2016-09-08 Methods of treating developmental disorders using pipradrol

Publications (1)

Publication Number Publication Date
MX2018002906A true MX2018002906A (es) 2018-06-08

Family

ID=56027680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002906A MX2018002906A (es) 2015-09-09 2016-09-08 Metodos de tratamiento de trastornos del desarrollo con pipradrol.

Country Status (12)

Country Link
US (4) US9351968B1 (es)
EP (1) EP3331527A4 (es)
JP (1) JP2018528215A (es)
KR (1) KR20180081710A (es)
CN (1) CN108366999A (es)
AU (1) AU2016318943A1 (es)
BR (1) BR112018004680A2 (es)
CA (1) CA2997923A1 (es)
HK (1) HK1255132A1 (es)
IL (3) IL257944B (es)
MX (1) MX2018002906A (es)
WO (1) WO2017044578A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180031721A (ko) 2015-07-17 2018-03-28 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
JP2019517469A (ja) 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
IL270180B (en) 2017-04-26 2022-06-01 Cavion Inc Methods to improve memory and cognition and to treat memory and cognition disorders
RU2767661C2 (ru) * 2017-04-26 2022-03-18 Кавион, Инк. Способы лечения синдрома драве
CN111201022A (zh) 2017-08-04 2020-05-26 奥维德医疗公司 加波沙朵在治疗糖尿病及相关状况中的用途
WO2019098630A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도
CN112930182A (zh) 2018-09-20 2021-06-08 奥维德医疗公司 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
EP3860571A4 (en) 2018-10-03 2022-06-29 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
WO2003013514A1 (en) * 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US8865746B2 (en) 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
WO2011147889A1 (en) 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
JP2019517469A (ja) 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法

Also Published As

Publication number Publication date
US9913833B2 (en) 2018-03-13
US20170216269A1 (en) 2017-08-03
EP3331527A1 (en) 2018-06-13
IL282655A (en) 2021-06-30
CA2997923A1 (en) 2017-03-16
KR20180081710A (ko) 2018-07-17
IL257944A (en) 2018-05-31
IL282580A (en) 2021-06-30
JP2018528215A (ja) 2018-09-27
HK1255132A1 (zh) 2019-08-09
EP3331527A4 (en) 2019-04-10
WO2017044578A1 (en) 2017-03-16
BR112018004680A2 (pt) 2018-09-25
IL257944B (en) 2021-05-31
US9351968B1 (en) 2016-05-31
US20180147195A1 (en) 2018-05-31
US20170065572A1 (en) 2017-03-09
CN108366999A (zh) 2018-08-03
AU2016318943A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
NZ730809A (en) Methods for treating filoviridae virus infections
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
MX2019012285A (es) Metodos de tratamiento de encefalopatias del desarrollo.
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12017501735A1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX345534B (es) Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas.
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
PH12018500814A1 (en) Oxadiazaspiro compounds for the treatment of drug abuse and addiction
MX2017013281A (es) Metodos para tratar transtornos del almacenamiento lisosomal.
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain